Search

Displaying results 2771 - 2780 of 8517 in total
  1. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.

  2. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. … Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.

  3. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor. … Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

  4. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    -1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease [A175957]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment

  5. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.

  6. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    As an experimental drug, agmatine is being studied for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma … As an investigational drug, it is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy between the

  7. Drug

    Etynodiol

    go.drugbank.com/drugs/DB13866
    Experimental

    Etynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed. … While etynodiol is sometimes used as a synonym for etynodiol diacetate, it usually refers to etynodiol diacetate (see [DB00823]), not etynodiol.

  8. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  9. Drug

    Silver

    go.drugbank.com/drugs/DB12965
    ApprovedInvestigational

    It has a high electrical conductivity, thermal conductivity, and reflectivity. Silver exists as a pure elemental form, alloy with other metals, and mineral. … [DB11080] and [DB05245] have been used as topical antibacterial agents for the treatment of skin infections, while [DB05245] has also been valued for topical burn treatment [A33141].

  10. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L10169] It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. … [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017.